New York, Feb 2, 2026, 13:20 ET — Regular session
- Shares of IDEAYA Biosciences jumped about 5% on Monday, beating biotech ETFs.
- Two investor events are lined up for February, with senior executives set to deliver talks.
- Investors are watching for Q1 trial results tied to IDEAYA’s flagship uveal melanoma program.
Shares of IDEAYA Biosciences climbed about 5% on Monday, lifted by a broad upswing in biotech stocks. Investors zeroed in on the company ahead of two executive presentations scheduled for February.
IDEAYA is heading into a stretch where investors expect clearer updates on clinical milestones. The stock often moves decisively whenever those timelines shift.
In January, IDEAYA set a target for topline results from its registrational OptimUM-02 trial in first-line HLA*A2-negative metastatic uveal melanoma by Q1 2026. This includes progression-free survival (PFS) data, which measures how long patients live without their cancer worsening. The company also outlined plans to push forward four registrational trials throughout 2026 and confirmed its cash runway stretches into 2030. CEO Yujiro S. Hata highlighted the importance of darovasertib trials in their mission to “save eyes, preserve vision, and extend lives” for uveal melanoma patients. Investor Relations | IDEAYA Biosciences
On Monday, the South San Francisco-based company revealed it will participate in Citi’s 2026 Virtual Oncology Leadership Summit on Feb. 18. The lineup includes a fireside chat with Chief Medical Officer Darrin Beaupre, Chief Scientific Officer Michael White, and Chief Financial Officer Joshua Bleharski. Another virtual fireside chat is scheduled for Feb. 23, hosted by Evercore ISI’s Umer Raffat, where Hata will join Beaupre, White, and Bleharski, according to the announcement.
IDEAYA shares jumped 5.1%, hitting $33.83 in early New York trading. The SPDR S&P Biotech ETF nudged higher by roughly 1.9%, and the iShares Nasdaq Biotechnology ETF ticked up about 0.9%.
U.S. stocks pushed higher across the board. The S&P 500 tracker SPY added about 0.7%, with the Nasdaq 100 tracker QQQ up nearly 1.0%, boosting sentiment for riskier biotech names.
Traders are watching for any changes in the expected timing of the OptimUM-02 readout. They’ll be paying close attention to management’s plan for an FDA filing if the results are positive, particularly which data beyond PFS still needs to be proven.
IDEAYA is broadening its reach into antibody-drug conjugates and other precision oncology projects, adding layers of complexity for investors. Yet, the immediate attention stays fixed on darovasertib and the data expected soon.
Still, this setup can turn against investors just as fast. A delayed key readout or weak efficacy or safety data tends to hit clinical-stage biotech stocks hard, regardless of how stable the broader market may be.
Feb. 18 brings Citi’s virtual oncology summit, with Evercore ISI’s fireside chat set for Feb. 23 just days later. Both events are expected to shed light on the upcoming quarter’s uveal melanoma update investors have been waiting on.
